×
×
PrismRA Molecular Signature Test

Join Our Newsletter

Learn more about how PrismRA can help guide your RA treatment with our patient focused newsletter.

Address

By clicking Submit you agree to receive marketing emails from PrismRA

  • Join Newsletter
  • Login
  • Contact Us
  • Search
Prism RA
  • Get PrismRA
  • The PrismRA Result
  • For Physicians
  • Affordability
  • Lab & Sample Collection
Select Page
  • Get PrismRA
  • The PrismRA Result
  • For Physicians
  • Affordability
  • Lab & Sample Collection
  • Join Newsletter
  • Login
  • Contact Us
  • Search

PrismRA Was Developed & Clinically Validated to Guide RA Therapy Selection

by Stu Steene-Connelly | Jun 15, 2024 | Science & Technology

PrismRA Was Developed & Clinically Validated to Guide RA Therapy Selection PrismRA® is a blood-based precision medicine test that was developed using the science of the human interactome to help guide the treatment of rheumatoid arthritis. The human interactome is...

Examining the Clinical Utility of PrismRA

by Stu Steene-Connelly | May 15, 2024 | Patient Empowerment, Science & Technology

Examining the Clinical Utility of PrismRA PrismRA® is a blood-based precision medicine test used by over 1,400 advanced practitioners around the country to guide the treatment selection in their patients with rheumatoid arthritis. While validated precision medicine...

Current Care Therapy Selection for RA Relies on Trial-and-Error

by Stu Steene-Connelly | Apr 30, 2024 | Science & Technology

Current Care Therapy Selection for RA Relies on Trial-and-Error Rheumatoid arthritis (RA) affects roughly 1.6 million people in the US and as much as 1% of the population worldwide.1 This chronic autoimmune disease attacks the lining of the joints on both sides of the...
PrismRA Molecular Signature Test

PrismRA is a molecular signature response classifier (MSRC) that uses gene expression features, clinical features and anti-cyclic citrullinated protein (anti-CCP) antibody to detect a signature of non-response to tumor necrosis factor-α inhibitors (TNFi) for patients with rheumatoid arthritis. PrismRA predicts the patient’s likelihood of inadequately responding to all TNFi therapies. Response is defined as achieving ACR50 at 6 months. The PrismRA result is reported on a continuous 1 to 25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies. However, a low score does not ensure a positive response to TNFi therapies.

PrismRA for Patients

  • How PrismRA Helps You
  • Get PrismRA
  • The PrismRA Result
  • Find a Provider
  • Affordability
  • Join the Newsletter
  • Billing FAQs

For Physicians

    • Clinical Content
    • The PrismRA Solution
    • PrismRA Development
    • The PrismRA Result Report
    • Ordering PrismRA
    • Publications & Tech Specs

Resources

  • Patient Brochure
  • Folleto Para Pacientes
  • Billing Brochure
  • Folleto Para Facturación
  • Financial Assistance
  • Patient Billing Portal
  • How to Talk to Your Doctor
  • Global Healthy Living Foundation

Scipher Medicine

  • Contact Us
  • PrismRA Lab Certifications
  • Scipher Lab Service Guide
  • Notice of Privacy Practices
  • Privacy Policy
  • Terms of Use
  • Cookies Acknowledgement
  • Patient Opt-Out Information
  • Right to Receive a Good Faith Estimate
  • Notice of Nondiscrimination
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

2023 Scipher Medicine Corporation. All rights reserved. Scipher Medicine, PrismRA, and their logos are registered trademarks in the United States and other jurisdiction. RA-SA0004-003-230206

Notifications